Feb 28, 2022

• Introduction (0:00)
• Case: A woman in her late 60s with newly diagnosed extensive-stage small-cell lung cancer (ES-SCLC) who receives carboplatin/etoposide/atezolizumab — Luis Paz-Ares, MD, PhD (13:22)
• Case: A woman in her mid-40s with newly diagnosed ES-SCLC who receives carboplatin/etoposide/durvalumab — Jared Weiss, MD (29:43)
• Case: A man in his early 60s with ES-SCLC who receives carboplatin/etoposide/durvalumab and then experiences disease progression — Dr Paz-Ares (38:08)
• Case: A man in his early 70s with progressive SCLC who receives lurbinectedin — Dr Paz-Ares (45:15)
• Case: A man in his early 80s with SCLC who experiences disease progression — Dr Weiss (54:46)

CME information and select publications